Field Medical Unveils Breakthrough Field PULSE Trial Data at AF Symposium 2026
Field Medical, Inc., a clinical-stage medical technology company, has presented significant findings from its Field PULSE study at the 31st Annual International AF Symposium 2026 in Boston. The study focuses on a novel pulsed field ablation (PFA) technology designed to treat complex cardiac arrhythmias. Utilizing the FieldForce Ablation System, the study demonstrated the ability to perform instantaneous ablation through high-voltage waveforms, achieving rapid point-by-point energy delivery without the need for prolonged tissue-catheter contact. The trial was highlighted as a Late Breaking Clinical Trial, underscoring its importance in the field. Key findings include the creation of lesions in under 200 milliseconds and a median bilateral pulmonary vein isolation time of 12.5 minutes, with no device-related serious adverse events reported. 
